Supplemental Table 1. Schedule of Key Study Activities

Activity	Screening (Day −28 to Day −1)	Treatment period (Day 1 to Week 26)									PTFU
				± 3 days		± 5 days					
		Day 1	Day 2[a]	Week 1 (Day 8)	Week 4 (Day 29)	Week 8 (Day 57)	Week 12 (Day 85)	Week 16 (Day 113)	Week 20 (Day 141)	Week 26 (Day 183)	
Laboratory/Safety Assessments											
12-lead ECG	X	X			X		X			X	
Clinical lab samples (hematology, chemistry, and urinalysis)	X	X		X	X	X	X	X	X	X	X
Physical exam	X	X			X		X			X	X
Vital signs	X	X	X	X	X	X	X	X	X	X	X
Orthostatic evaluations	X	X	X	X	X	X	X	X	X	X	X
Adverse events		From first dose throughout study[b]									
PK and Biomarker Assessments											
PK sampling: sparse and intensive substudy[c]		X			X		X			X	
Blood samples for exploratory biomarkers		X			X		X			X	
Efficacy Assessments											
HRCT	X									X	
Spirometry	X	X			X	X	X	X	X		
D_{LCO} SB	X	X					X			X	
Clinical Outcome Assessments											
PROs: L-PF, SGRQ, UCSD SOBQ, Cough VAS		X					X			X	
6MWT		X					X			X	
O_2 titration	X										

[a]Clinic visits at this time point are only required for those participants who meet low blood pressure criteria on Day 1; [b]Additionally, serious adverse events will be collected from time of informed consent until 30 days from the last visit; [c]Serial ECGs will be collected and blood pressure and heart rate will be measured at each time point for patients in the intensive PK substudy. 6MWT, 6-minute walk test; DLCO SB, single-breath diffusing capacity of the lung; ECG, electrocardiogram; HRCT, high resolution computed tomography; L-PF, Living with Pulmonary Fibrosis Questionnaire; PK, pharmacokinetics; PRO, patient-reported outcome; PTFU, posttreatment follow-up; SGRQ, St. George's Respiratory Questionnaire; UCSD SOBQ, University of California San Diego Shortness of Breath Questionnaire; VAS, visual analogue scale.